Description: GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
Home Page: www.genels.com
The Pinnacle Gangnam
Seoul,
06060
South Korea
Phone:
82 2 6004 3450
Officers
| Name | Title |
|---|---|
| Mr. Young-Keun Park J.D., M.B.A. | CEO & Director |
| Mr. Byung-Mun Cho B.A., M.B.A. | Exec. VP & Exec. Director |
| Je-Kyung Che | Exec. |
| Han-Mo Park | Exec. |
| Ho-Joon Lee | Exec. |
| Won-Young Jeong | Exec. |
| Nak-Young Kim | Exec. |
| Heung-Won Seo | Exec. |
| Chang-Hoon Song | Exec. |
| Yoon-Jin Lee | Exec. |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Consumer Discretionary |
|---|---|
| GIC Group: | Consumer Durables & Apparel |
| GIC Industry: | Textiles, Apparel & Luxury Goods |
| GIC Sub-Industry: | Apparel, Accessories & Luxury Goods |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8369 |
| Price-to-Sales TTM: | 14.3 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 61 |